UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Annals of the rheumatic diseases, 2017-07, Vol.76 (7), p.1253-1262

2017

Volltextzugriff (PDF)

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Rheumatic & musculoskeletal diseases open, 2023-02, Vol.9 (1), p.e002735

2023

Volltextzugriff (PDF)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Rheumatic & musculoskeletal diseases open, 2020-10, Vol.6 (3), p.e001395

2020

Volltextzugriff (PDF)

Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)

Clinical rheumatology, 2022-04, Vol.41 (4), p.1045-1055

2022

Volltextzugriff (PDF)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Arthritis research & therapy, 2018-07, Vol.20 (1), p.155-155, Article 155

2018

Volltextzugriff (PDF)

Malignancy and Janus Kinase Inhibition

Rheumatic diseases clinics of North America, 2017-02, Vol.43 (1), p.79-93

2017

Volltextzugriff (PDF)

Oral surveillance and JAK inhibitor safety: the theory of relativity

Nature reviews. Rheumatology, 2022-05, Vol.18 (5), p.301-304

2022

Volltextzugriff (PDF)

JAK inhibitors and VTE risk: how concerned should we be?

Nature reviews. Rheumatology, 2021-03, Vol.17 (3), p.133-134

Cohen, Stanley B.

2021

Volltextzugriff (PDF)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Rheumatology and therapy., 2023-10, Vol.10 (5), p.1255-1276

2023

Volltextzugriff (PDF)

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Rheumatology and therapy., 2024-02, Vol.11 (1), p.221-222

2024

Volltextzugriff (PDF)

Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept

Journal of rheumatology, 2006-04, Vol.33 (4), p.712

2006

Volltextzugriff (PDF)

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Annals of the rheumatic diseases, 2021-03, Vol.80 (3), p.304-311

2021

Volltextzugriff (PDF)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the rheumatic diseases, 2018-06, Vol.77 (6), p.914-921

2018

Volltextzugriff (PDF)

Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

Rheumatic & musculoskeletal diseases open, 2021-06, Vol.7 (2), p.e001673

2021

Volltextzugriff (PDF)

Targeting the B Cell in Rheumatoid Arthritis

Best practice & research. Clinical rheumatology, 2010-08, Vol.24 (4), p.553-563

Cohen, Stanley B., MD

2010

Volltextzugriff (PDF)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Rheumatology and therapy., 2023-04, Vol.10 (2), p.357-373

2023

Volltextzugriff (PDF)

Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis

Arthritis & rheumatology (Hoboken, N.J.), 2018-02, Vol.70 (2), p.204-211

2018

Volltextzugriff (PDF)

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study

Journal of bone and joint surgery. American volume, 2018-04, Vol.100 (8), p.666-677

2018

Volltextzugriff (PDF)

Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al

Arthritis & rheumatology (Hoboken, N.J.), 2021-08, Vol.73 (8), p.1567-1569

2021

Volltextzugriff (PDF)

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

Annals of the rheumatic diseases, 2013-03, Vol.72 (3), p.329-336

2013

Volltextzugriff (PDF)

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

Annals of the rheumatic diseases, 2017-09, Vol.76 (9), p.1598-1602

2017

Volltextzugriff (PDF)

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

Expert opinion on biological therapy, 2019-10, Vol.19 (10), p.1097-1105

2019

Volltextzugriff (PDF)

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

Arthritis research & therapy, 2011-07, Vol.13 (4), p.R125-R125, Article R125

2011

Volltextzugriff (PDF)

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

Journal of rheumatology, 2004-06, Vol.31 (6), p.1098

2004

Volltextzugriff (PDF)

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

Rheumatology (Oxford, England), 2021-01, Vol.60 (1), p.256-262

2021

Volltextzugriff (PDF)

1 – 25 von 649

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(579)
Mit Volltextzugriff
(501)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(649)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(406)
Life Sciences & Biomedicine
(339)
Humans
(274)
Female
(145)
Male
(139)
Biological And Medical Sciences
(115)
Animals
(101)
Medical Sciences
(89)
Middle Aged
(89)
Adult
(79)
Rheumatology
(79)
Aged
(55)
Biochemistry & Molecular Biology
(55)
Mice
(55)
Rheumatoid Arthritis
(54)
Treatment Outcome
(53)
Arthritis, Rheumatoid - Drug Therapy
(49)
Multidisciplinary Sciences
(47)
Science & Technology - Other Topics
(47)
Prions - Chemistry
(45)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Malignancy and Janus Kinase Inhibition

Oral surveillance and JAK inhibitor safety: the theory of relativity

JAK inhibitors and VTE risk: how concerned should we be?

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

Targeting the B Cell in Rheumatoid Arthritis

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Brief Report: A Phase IIb Trial of a Novel Extended‐Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study

Use of Precision Medicine to Guide Treatment of Patients With Rheumatoid Arthritis: Comment on the Article by Tao et al

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

Suchergebnisse filtern